EANM’s 39th Congress opens Saturday in Vienna on the back of a week stacked with fresh PSMA radioligand data: Telix’s upcoming interim results for 177Lu-panPSMA and a 62% risk-reduction follow-up from the LUNAR trial, published this week in European Urology. At the same time, Lantheus shareholders cleared the $8 billion Curium merger, and GE HealthCare expanded its PET isotope production footprint. Clinical momentum and supply-chain consolidation are now moving on the same calendar, and programs should be watching both.

A European Urology follow-up of the Phase 2 LUNAR trial found that giving 177Lu-PNT2002 before stereotactic ablative radiotherapy cut the risk of progression, added hormone therapy, or death by 62% compared with SBRT alone, at a median follow-up of 31.9 months, in men with oligorecurrent, hormone-sensitive prostate cancer. A third of combination patients had no detectable cancer at two years, versus 12% with SBRT alone, with no new safety signals — the clearest sign yet that sequencing radioligand therapy earlier, before disease becomes widespread, has a durable payoff.

Telix will present topline Phase 3 data at EANM for its Illuccix PSMA PET imaging agent in Chinese men with biochemical recurrence, as part of a broader data package that also includes interim results for its 177Lu-panPSMA radioligand candidate in mCRPC.

A Journal of Nuclear Medicine preclinical study evaluated a radiohybrid rhPSMA-10.1 ligand labeled with both fluorine-18 and actinium-225, reporting tumor targeting and dosimetry that support a combined PSMA PET imaging and alpha-therapy pairing — an early but notable step toward theranostic agents built on a single molecular scaffold.

Lantheus shareholders voted October 14 to approve the Curium merger, clearing the deal’s key shareholder hurdle with more than 55.4 million votes in favor; Curium will acquire Lantheus for $102.50 per share in cash plus contingent value rights worth up to $12 per share, with the deal still subject to remaining regulatory approvals and an expected close in the first half of 2027.

GE HealthCare’s MINItrace Magni cyclotron won CE Mark approval for on-site radioisotope production, and the company expanded its PETtrace Solid Target Platform to add copper-64 — both moves aimed at broadening PET and theranostic tracer capacity closer to the point of care.

Eckert & Ziegler Brazil and TerThera signed a supply agreement for GMP-grade, carrier-free terbium-161, restoring a South American radioisotope pipeline TerThera last supplied six years ago and giving Brazilian developers direct access to next-generation radioligand therapy ingredients.